Intranasal administration of convalescent plasma protects against SARS-CoV-2 infection in hamsters

BACKGROUND: Convalescent plasma (CP) transfusion is an early option for treating infections with pandemic potential, often preceding vaccine or antiviral drug rollout. Heterogenous findings from randomized clinical trials on transfusion of COVID-19 CP (CCP) have been reported. However, meta-analysis...

Descripción completa

Detalles Bibliográficos
Autores principales: Wouters, Elise, Verbrugghe, Caro, Abdelnabi, Rana, Devloo, Rosalie, De Clippel, Dorien, Jochmans, Dirk, De Bleser, Dominique, Weynand, Birgit, Compernolle, Veerle, Neyts, Johan, Feys, Hendrik B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171892/
https://www.ncbi.nlm.nih.gov/pubmed/37148586
http://dx.doi.org/10.1016/j.ebiom.2023.104597

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171892/
https://www.ncbi.nlm.nih.gov/pubmed/37148586
http://dx.doi.org/10.1016/j.ebiom.2023.104597

Ejemplares similares